Kane Biotech Successfully Completes Safety and Biocompatibility Studies for DispersinB® Wound Gel in Preparation for Human Clinical Trials Mar 22, 2022
Kane Biotech to Release Fourth Quarter and Full Year 2021 Financial Results on March 24 – Conference Call to Follow Mar 17, 2022
Kane Biotech Announces New Collaboration Agreements for Prosthetic Joint Infection, expanding its DispersinB® applications Feb 10, 2022
Kane Biotech to Release Third Quarter 2021 Financial Results on November 16 – Conference Call to Follow Nov 9, 2021
